| 查看: 330 | 回复: 0 | |||
[交流]
Vivitrol和抑郁：病例报告及文献复习
|
|
The introduction of a long-acting depot formulation of naltrexone (Vivitrol), FDA approved for the treatment of alcohol and opioid dependence in 2006 and 2010, respectively, has raised safety concerns including: (1) risk of development or exacerbation of depressive symptoms during treatment; and (2) increased risk of opioid overdose after treatment cessation. The concern that treatment with long-acting naltrexone may lead to depressive symptoms has a plausible theoretical basis given the medication’s blockade of μ-opioid receptors, which, when activated, lead to positive mood states. Risk of depression and suicidality are listed as potential adverse reactions in the manufacturer’s insert and are commonly relayed to patients during informed consent for treatment (http://www.vivitrol.com/About/Safety). However, these concerns may not be substantiated. Given that depression is commonly comorbid with alcohol and opioid dependence, concerns about the exacerbation of depression could prevent many individuals from receiving beneficial treatment as more evidence emerges supporting the efficacy of depot naltrexone. A recent multisite randomized trial found that opioid-dependent subjects receiving long-acting naltrexone were far more likely to remain abstinent over 6 months of treatment (median of 90% abstinent weeks for naltrexone group vs. 35% for placebo group). In this paper, we review the existing literature on the effects of short-acting and long-acting naltrexone on mood as well as effects on preexisting depressive disorders, with the aim of assisting clinicians in selecting appropriate patients for treatment with this medication. provide：www.tianyuan520.com |
回复此楼» 本帖附件资源列表
-
欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com - 附件 1 : 00132576-201409000-00007.pdf
2014-09-30 15:38:12, 99.98 K
» 猜你喜欢
求验证
已经有20人回复
-
脑中的P物质怎么检测？
已经有1人回复
-
康复医学论文润色/翻译怎么收费?
已经有257人回复
-
Western blot 问题求助
已经有0人回复
-
关于Springer杂志社下International orthopaedics的疑问。
已经有10人回复
-
Food ， Function这个杂志的综述好投吗？
已经有7人回复
-
【求助】rBMSC细胞培养的过程中有可疑造血干细胞长起，该如何去除？
已经有3人回复
-
博士后面上项目申请书生成后，最后的签字页在哪里提交？
已经有5人回复
-
211本硕求博自荐信
已经有10人回复
-
Phytomedicine的作者同意声明
已经有0人回复
